Evidence map›Paper›PMID 28679535›Full record

ArticleThe Journal of biological chemistry2017

Small molecule-based inhibition of MEK1/2 proteins dampens inflammatory responses to malaria, reduces parasite load, and mitigates pathogenic outcomes.

Xianzhu Wu, Kiran K Dayanand, Ramesh P Thylur, Christopher C Norbury, D Channe Gowda

Open access · hybridAbstract readComparative Study
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. IL-4Rα signaling by CD8αThe Journal of biological chemistry
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xianzhu WuFrom the Departments of Biochemistry and Molecular Biology and.
Kiran K DayanandFrom the Departments of Biochemistry and Molecular Biology and.
Ramesh P ThylurFrom the Departments of Biochemistry and Molecular Biology and.
Christopher C NorburyMicrobiology and Immunology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033.
D Channe GowdaFrom the Departments of Biochemistry and Molecular Biology and gowda@psu.edu.ORCID 0000-0002-6860-5108
Goodwin College · USPennsylvania State University · US

Funding

Innate Immune Responses to Malaria ParasitesR01AI041139 · NIAID · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI GOWDA, CHANNE D · 1998 to 2017
$5.8M
Malaria Research Training in South IndiaD43TW008268 · FIC · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI GOWDA, CHANNE D · 2010 to 2015
$682k
FIC NIH HHS D43 TW008268NIAID NIH HHS R01 AI041139
6 · The paper itself

Abstract

Malaria infections cause several systemic and severe single- or multi-organ pathologies, killing hundreds of thousands of people annually. Considering the existing widespread resistance of malaria parasites to anti-parasitic drugs and their high propensity to develop drug resistance, alternative strategies are required to manage malaria infections. Because malaria is a host immune response-driven disease, one approach is based on gaining a detailed understanding of the molecular and cellular processes that modulate malaria-induced innate and adaptive immune responses. Here, using a mouse cerebral malaria model and small-molecule inhibitors, we demonstrate that inhibiting MEK1/2, the upstream kinases of ERK1/2 signaling, alters multifactorial components of the innate and adaptive immune responses, controls parasitemia, and blocks pathogenesis. Specifically, MEK1/2 inhibitor treatment up-regulated B1 cell expansion, IgM production, phagocytic receptor expression, and phagocytic activity, enhancing parasite clearance by macrophages and neutrophils. Further, the MEK1/2 inhibitor treatment down-regulated pathogenic pro-inflammatory and helper T cell 1 (Th1) responses and up-regulated beneficial anti-inflammatory cytokine responses and Th2 responses. These inhibitor effects resulted in reduced granzyme B expression by T cells, chemokine and intracellular cell adhesion molecule 1 (ICAM-1) expression in the brain, and chemokine receptor expression by both myeloid and T cells. These bimodal effects of the MEK1/2 inhibitor treatment on immune responses contributed to decreased parasite biomass, organ inflammation, and immune cell recruitment, preventing tissue damage and death. In summary, we have identified several previously unrecognized immune regulatory processes through which a MEK1/2 inhibitor approach controls malaria parasitemia and mitigates pathogenic effects on host organs.

Indexed as

Adaptive ImmunityAnimalsAntimalarialsBone Marrow CellsCells, CulturedCoculture TechniquesDendritic CellsFemaleFlavonoidsImmunity, InnateKiller Cells, NaturalMalaria, CerebralMalaria, FalciparumMaleMAP Kinase Kinase 1MAP Kinase Kinase 22-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-oneAntimalarialsFlavonoidsMAP Kinase Kinase 1MAP Kinase Kinase 2Protein Kinase InhibitorsProtozoan ProteinsPyridonesPyrimidinonestrametinibinflammationmalariamitogen-activated protein kinase (MAPK)pathogenesisphagocytosis

Identifiers

PMID28679535
PMCPMC5566520
OpenAlexW2729684361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.